RxDoctor Payments DataLook up a doctor →

Emily Riser, MD

Neurology · Birmingham, ALNPI 1124115068

Payments from drug & device makers

$7,097,450in general payments, 2019–2025

Across 1,581 payments — averaging $4489.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2M
  • Genentech, Inc.$1.7M
  • Sanofi$1.2M
  • TG Therapeutics, Inc.$956K
  • EMD Serono, Inc.$654K
  • Biogen$234K
  • plus $436K from 49 others
$1,477in research payments, 2019–2025

Across 2 payments — averaging $738.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis49$1,974,883
Genentech, Inc.142$1,684,267
Sanofi64$1,157,353
TG Therapeutics, Inc.122$955,965
EMD Serono, Inc.116$654,485
Biogen141$234,206
Roche Products Limited185$193,691
AstraZeneca108$146,784
Bristol Myers Squibb54$65,744
Genentech USA, Inc.52$12,367
Amgen(2 entities)95$6,401
Mallinckrodt Hospital Products Inc.36$3,786
Neurocrine Biosciences, Inc.37$922
UCB, Inc.30$768
AbbVie(2 entities)68$673
Pfizer38$670
Tanabe Pharma America, Inc.36$656
Lilly USA, LLC29$369
Argenx US, Inc.17$303
Johnson & Johnson(2 entities)10$295
Banner Life Sciences, LLC9$257
Acadia Pharmaceuticals Inc12$228
Acorda Therapeutics, Inc13$211
Teva Pharmaceuticals USA, Inc.14$183
Assertio Therapeutics, Inc.11$172
Eisai Inc.7$162
Biohaven Pharmaceuticals, Inc.6$151
Lundbeck LLC7$144
Neurelis, Inc.10$144
CSL Behring6$140
ANI Pharmaceuticals, Inc.4$117
Adamas Pharmaceuticals, Inc.4$84
Harmony Biosciences LLC3$75
Grifols USA, LLC4$73
Avanir Pharmaceuticals, Inc.4$69
Cycle Pharmaceuticals Inc4$64
Arbor Pharmaceuticals, Inc.4$62
Octapharma USA, Inc.2$48
Boston Scientific2$48
E.r. Squibb & Sons, L.L.C.4$47
Takeda Pharmaceuticals U.S.A., Inc.2$46
Jazz Pharmaceuticals Inc.2$44
Axsome Therapeutics, Inc.2$42
Catalyst Pharmaceuticals, Inc.2$31
Biohaven Pharmaceutical Holding Company Ltd.2$30
Upsher-smith Laboratories LLC2$30
MDD US Operations, LLC2$27
Amylyx Pharmaceuticals, Inc.1$24
Sanofi-aventis U.S. LLC1$20
Otsuka America Pharmaceutical, Inc.1$20
Mallinckrodt Enterprises LLC1$18
Kedrion Biopharma, Inc.1$17
Amneal Pharmaceuticals LLC1$13
Zyla Life Sciences, Inc.1$13
Supernus Pharmaceuticals, Inc.1$11

How this compares

$7,097,450 in reported general payments places this provider in the 95th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024
$1,186,198
Medicare patients
215
Services billed
34,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →